Skip to main content

Table 1 Characteristics of Studies Included

From: Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis

Author

Year

Country

City

Design

HBOC/HBC

Age at Diagnosis (range or mean)

Mutation type

Test type

Sample size

Sample size of HBOC

Abdel-Razeq

2018

Jordan

–

Pilot study

HBCb

22–75

Deleterious

Suspected-deleterious

BART1

100

84

Bu

2016

Saudi Arabia

–

Cross-sectional

HBC

41.9

Deleterious

PCR2, CS3/SS4, and TCS5

818

60

Bujassoum

2017

Qatar

–

Retroa

HBC

23–68

Deleterious

MLPA6

82

82

Cherbal

2015

Algeria

High Plains

Cross-sectional

HBOCc

< 50

Deleterious

VUS

PCR2

192

192

El Saghir

2015

Lebanon

Beirut

Cross-sectional

HBC

40.8

Deleterious

VUS

MLPA6

250

74

Ibrahim

2010

Egypt

Alexandria

Registry data

HBC

43.5

Deleterious

SSCP7

HAC8

60

39

Jalkh

2012

Lebanon

–

Cross-sectional

HBC

41

Deleterious

VUS

Polymorphisms

Fluorescent DS9

72

72

Kadouri

2007

Palestine

East Jerusalem

Cross-sectional

HBC

–

Deleterious

VUS

Polymorphisms

DHPLC10

31

10

Laarabi

2017

Morocco

North-East morocco (Rabat, Fes, Oujda)

Cross-sectional

HBOC

–

Deleterious

CSS11

NGS12

TS13

122

122

Laraqui

2013

Morocco

Rabat

Retro

HBC

–

Deleterious

DS14

121

19

Mahfoudh

2012

Tunisia

Sousse

Cross-sectional

HBC

29–65

Deleterious

VUS

Polymorphisms

DS15

24

24

Riahi

2016

Tunisia

–

Cross-sectional

HBC

–

Deleterious

Logistic regression model (studied three studies)

92

92

Tazzite

2012

Morocco

Casablanca

Case series

HBOC

25–60

Deleterious

DS15

40

34

Uhrhammer

2008

Algeria

Algiers

Pilot study

HBC

15–52

Deleterious

VUS

Polymorphisms

PCR2

64

13

  1. aRetro: retrospective cohort study
  2. bHBC: hereditary breast cancer
  3. cHBOC: hereditary breast and/or ovarian cancer
  4. 1BART: Comprehensive BRACAnalysis and BRACAnalysis rearrangement test
  5. 2PCR: Polymerase chain reaction
  6. 3CS: Capture sequencing
  7. 4SS: Sanger sequencing
  8. 5TCS: Targeted capture sequencing
  9. 6MLPA: Multiple ligation dependent probe amplification
  10. 7SSCP: single strand conformation polymorphism assay
  11. 8HAC: Heteroduplex assay confirmation
  12. 9Fluorescent direct sequencing of the entire coding region and intronic sequence flanking each exon
  13. 10DHPLC: denaturing high performance liquid chromatography
  14. 11CSS: Conventional individual exon-by-exon Sanger sequencing
  15. 12NGS: Next generation sequencing
  16. 13TS: Target screening for exon 10 in BRCA2
  17. 14Direct sequencing of all coding exons and flanking intron sequences of the BRCA1 gene
  18. 15DS: Direct Sequencing
  19. 16Direct sequencing